• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular OutcoMes for People Using Anticoagulation StrategieS (COMPASS) Trial
Conclusion COMPASS will provide information on the efficacy and safety of rivaroxaban, alone or in combination with aspirin, in the long-term management of patients with stable CAD or PAD, and on the efficacy and safety of pantoprazole in preventing upper GI complications in patients receiving antithrombotic therapy. Teaser COMPASS is a global randomized controlled trial comparing rivaroxaban 2.5mg twice-daily plus aspirin 100mg once-daily, rivaroxaban 5mg twice-daily, and aspirin 100mg once-daily for prevention of myocardial infarction, stroke, or cardiovascular death in patients with stable coronary or peripheral artery ...
Source: Canadian Journal of Cardiology - June 8, 2017 Category: Cardiology Source Type: research

Cost-Effectiveness of Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation Patients with Contraindications to Anticoagulation
Conclusions LAAC is a novel stroke preventative therapy for non-valvular AF and is a cost-effective alternative to aspirin in patients with contraindications to OAC. Teaser We sought to evaluate the cost-effectiveness of left atrial appendage closure (LAAC) compared to aspirin in atrial fibrillation patients with contraindications to oral anticoagulation (OAC). A probabilistic patient-level Markov microsimulation model with lifetime horizon was performed. Aspirin was less effective than LAAC, with average discounted lifetime cost of $38,974±18,783 for aspirin and $30,748±11,600 for LAAC. LAAC was dominant, being more eff...
Source: Canadian Journal of Cardiology - February 25, 2016 Category: Cardiology Source Type: research

A risk assessment tool incorporating new biomarkers for cardiovascular events in acute coronary syndromes: the Organization to Assess Strategies in Ischemic Syndromes (OASIS) risk score
Conclusions The addition of NT-proBNP and hemoglobin A1C to 5 standard variables creates a 7-variable risk score that improves prediction of cardiovascular events at 1 year and aids in risk-based selection of NSTEACS patients for dual antiplatelet therapy. Teaser Several new biomarkers improve risk stratification in non-ST-segment elevation ACS, however they are not integrated into risk prediction tools. A risk score to predict CV death/MI/stroke was developed by incorporating new biomarkers with standard variables. The addition of NT-proBNP and hemoglobin A1C to 5 standard variables (age, prior MI/stroke, sex, ST-segment ...
Source: Canadian Journal of Cardiology - February 3, 2016 Category: Cardiology Source Type: research

Atrial Fibrillation Patients Categorized as “Not for Anticoagulation” According to the 2014 Canadian Cardiovascular Society Algorithm Are Not “Low Risk”
Conclusions Based on the 2014 CCS algorithm, the “OAC not recommended” subgroup can have a high 1-year stroke rate overall, showing that such patients are not “low risk.” Use of the ESC guideline approach (based on the CHA2DS2-VASc) offers refinement of stroke risk stratification in such patients.
Source: Canadian Journal of Cardiology - January 17, 2015 Category: Cardiology Source Type: research